CHATSWORTH, Calif., May 18, 2010 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, in outlining its major strategic initiatives for 2010 and beyond, told shareholders attending the Annual Meeting held here on Friday that the value created from its new product pipeline is now coming to fruition, as the Company is poised to begin generating its first revenues and earnings from five product releases in 2010, a pipeline that expands the Company’s addressable market opportunity to nearly $4 billion from $450 million previously.
